Galecto Stock News

BeiGene (NASDAQ:BGNE) and Galecto (NASDAQ:GLTO) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, analyst recommendations and dividends. Profitability This table compares BeiGene and Galectos net margins, return on equity and return on assets. Net Margins []

Galecto, Inc. (NASDAQ:GLTO) was the target of a significant increase in short interest in October. As of October 29th, there was short interest totalling 71,400 shares, an increase of 152.3% from the October 14th total of 28,300 shares. Currently, 0.8% of the companys stock are short sold. Based on an average trading volume of 163,000 []

Galecto, Inc. (NASDAQ:GLTO) was the target of a large growth in short interest during the month of October. As of October 29th, there was short interest totalling 71,400 shares, a growth of 152.3% from the October 14th total of 28,300 shares. Based on an average trading volume of 163,000 shares, the days-to-cover ratio is presently []

BOSTON, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced t

BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced

Galecto now has three ongoing Phase 2 clinical trials with three different drug candidates in three high value indications Galecto now has three ongoing Phase 2 clinical trials with three different dr

BOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the treatment of

BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced i

BOSTON and COPENHAGEN, Denmark, June 22, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a publicly listed, clinical stage biotechnology company focused on the development of novel treatments f

The stock price of Galecto Inc (NASDAQ: GLTO) increased by 60% today. This is why it happened.

BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced it

Galecto (GLTO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

BOSTON, March 29, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced

Tuesday, March 30, 2021 @ 2pm Eastern Time Tuesday, March 30, 2021 @ 2pm Eastern Time

Tuesday, March 30, 2021 @ 2pm Eastern Time. Tuesday, March 30, 2021 @ 2pm Eastern Time.